Table 4.

Effects of in vitro AMG and L-arginine on the pulsed APC immunity4-150

Treatment N Transfusion Week
Pre 2 4 6
None  33  04-151 45  —  70  — 90  —  
AMG (0.5 mM)  8  50 (n/s)  25 (P < .1)  50 (P < .05)  
AMG (1 mM)  19   10 (P < .02)   30 (P < .05)  50 (P < .01)  
AMG (1 mM)  + L-Arg (1 mM) 8  0  100 (P < .05)  100 (n/s) 100 (n/s) 
Treatment N Transfusion Week
Pre 2 4 6
None  33  04-151 45  —  70  — 90  —  
AMG (0.5 mM)  8  50 (n/s)  25 (P < .1)  50 (P < .05)  
AMG (1 mM)  19   10 (P < .02)   30 (P < .05)  50 (P < .01)  
AMG (1 mM)  + L-Arg (1 mM) 8  0  100 (P < .05)  100 (n/s) 100 (n/s) 
F4-150

APC were pulsed with donor platelets at a ratio of 10 platelets: 1 APC in the presence of the agents indicated, washed twice and 106 APC were transfused weekly.

F4-151

Data are expressed as the percentage of recipients with detectable antidonor antibody by flow cytometry (rounded to nearest 5%).

The χ2 test of independent proportions was used to compare the agent-treated pulsed APC groups against the nontreated pulsed APC group. (n/s indicates not significant).

or Create an Account

Close Modal
Close Modal